Drugmakers sue to block Trump Medicare plan tying US drug prices to lower foreign prices
The industry challenge targets mandatory most-favored-nation pricing for Medicare drugs, a policy projected to save $64.3B over 10 years but cut pharma revenue.
Law Commentary · +14 outlets
Roche signs $1.2B deal with China's Rona Therapeutics for RNAi obesity drug
The pact gives Roche an entry into the emerging ALK7 obesity target race, extending its recent streak of China licensing deals.
BioPharma Dive · +6 outlets
Pfizer to halt development of closely watched weight-loss drug
The decision removes a once-promising oral obesity candidate from Pfizer's pipeline, weighing on its metabolic disease ambitions.
BusinessWorld Online · +2 outlets
Zealand Pharma and Generate strike AI obesity drug deal worth up to $1.2B
The tie-up pairs Zealand's peptide expertise with Generate's AI-driven drug discovery platform for obesity candidates.
Reuters · +14 outlets
India's Supreme Court presses government for wider drug price controls, slams steep markups
The court questioned why margin caps apply only to anti-cancer drugs while demanding price controls across all essential medicines and devices.
The Financial Express · +10 outlets
South Korea flags first suspected vision-loss case linked to GLP-1 obesity drugs
The rare adverse event report adds to scrutiny of GLP-1 safety as the class expands into mainstream obesity treatment.
KED Global · +4 outlets
Bristol Myers Squibb reports mixed Phase 3 admilparant trial results, higher dose misses
Success at one dose but failure at the higher dose complicates the outlook for the lung fibrosis drug, and BMY shares fell.
Mugglehead Investment Magazine · +7 outlets
Compass Pathways achieves primary endpoint in Phase 3 treatment-resistant depression trial
The data lift the psychedelic therapy field, which also got a boost from a Trump order fast-tracking such treatments.
Stocktwits · +13 outlets
BioNTech trial misses progression-free survival endpoint
The miss is a setback for BioNTech's oncology pipeline as it looks to move beyond its COVID vaccine franchise.
Stock Titan · +14 outlets
Capricor faces make-or-break FDA panel for Duchenne cell therapy deramiocel
FDA documents painted a difficult picture for the therapy while 24-month data presented in Japan lifted shares earlier in the week.
Stocktwits · +2 outlets
Lilly builds $1.5B stockpile of experimental weight-loss drug, fights black market
The stockpile and counterfeiting battle illustrate intense demand for next-generation obesity treatments before launch.
www.polskieradio.pl · +2 outlets
Novo Nordisk files for Wegovy insurance coverage in South Korea amid price war
The move intensifies competition in Korea's obesity market ahead of Hanmi's expected epeleuton launch.
BigGo Finance · +1 outlets
Replimune's melanoma therapy gains analyst optimism after positive FDA panel outcome
The overwhelmingly positive panel vote raised perceived approval odds and sent REPL shares to their best day ever.
Stocktwits · +3 outlets
Vaccine stocks rally on reports of US-led push for cancer vaccines
The reported initiative would expand federal backing for therapeutic cancer vaccine development.
TradingView · +7 outlets
China sets target for 25% of global first-in-class drugs by 2030
The goal signals Beijing's push to move from generic manufacturing toward innovative drug leadership.
조선일보 · +14 outlets
FDA approves first once-monthly subcutaneous olanzapine LAI for schizophrenia
The approval gives patients a less frequent injectable option for long-acting schizophrenia treatment.
Pharmacy Times · +13 outlets
Novo Nordisk says obesity drug trial confirms weight loss
The trial result reinforces Novo's position in the competitive obesity market as it develops next-generation candidates.
BusinessWorld Online
Mirum Pharmaceuticals says LIVMARLI met Phase 3 EXPAND endpoint
The trial data support expanded use of the drug, with RBC Capital reiterating its rating on the stock.
Mugglehead Investment Magazine